Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

BSH 2018: Access to new agents

Written by | 11 May 2018

Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.

Real-world data shows details beyond the clinical trials

Written by | 21 Feb 2018

Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.

ASH 2017: Mixed results for new NHL therapies

Written by | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.

ASH 2017: ECHELON-1: Brentuximab vedotin plus AVD in HL produces PFS improvement

Written by | 19 Jan 2018

Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.

ASH 2017: Experts offer guidance on smouldering myeloma

Written by | 17 Jan 2018

Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.

Hesitation still surrounds use of ‘cure’ word in MM

Written by | 15 Jan 2018

Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.

ICML 2017: Highlights

Written by | 30 Jul 2017

Interviewer: Esther Drain Dr Toby Eyre (Oxford),  Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.

ICML 2017: How will Hodgkins lymphoma be managed in 2020?

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.

BSH 2017: Management of Asymptomatic Follicular Lymphoma

Written by | 24 Apr 2017

The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.

BSH 2017 Debate: Identification and novel management strategies are essential for double hit lymphoma

Written by | 14 Apr 2017

Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.

World Health Matters: Researchers explore therapy and outcomes in PTCL

Written by | 27 Feb 2017

Dr Andrei Shustov (University of Washington School of Medicine, Seattle, USA) summarises the advances in T-Cell lymphoma therapy at ASH 2016, including long term data in PTCL and ALCL…. read more.

ASH 2017: Hesitation still surrounds use of ‘cure’ word in MM

Written by | 17 Jan 2017

Article written by Tom Collins. Interview by Esther Drain. With technology that allows clinicians to determine minimal residual disease negativity down to the 10-6 level, the word “cure” hangs… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.